id
stringlengths 7
11
| context
stringlengths 24
527
| is_mult_event
bool 2
classes | annotations
list |
|---|---|---|---|
10987357_7 | When pilsicainide is prescribed in patients with coronary artery disease or renal dysfunction, close attention must be paid to avoid life-threatening arrhythmias due to high plasma concentrations of the drug. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"due\"]], \"start\": [[162]], \"entity_id\": [\"T13\"]}, \"Treatment\": {\"text\": [[\"pilsicainide\"]], \"start\": [[5]], \"entity_id\": [\"T9\"], \"Drug\": {\"text\": [[\"pilsicainide\"]], \"start\": [[5]], \"entity_id\": [\"T14\"]}}, \"Effect\": {\"text\": [[\"life-threatening arrhythmias\"]], \"start\": [[133]], \"entity_id\": [\"T12\"]}, \"Subject\": {\"text\": [[\"patients with coronary artery disease or renal dysfunction,\"]], \"start\": [[35]], \"entity_id\": [\"T10\"], \"Disorder\": {\"text\": [[\"coronary artery disease\"], [\"renal dysfunction\"]], \"start\": [[49], [76]], \"entity_id\": [\"T11\", \"T1\"]}}}"
}
]
}
] |
19018868_3 | We describe a case of severe aplastic anemia (AA) that was probably induced by lenalidomide. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[68]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"lenalidomide\"]], \"start\": [[79]], \"entity_id\": [\"T6\"], \"Drug\": {\"text\": [[\"lenalidomide\"]], \"start\": [[79]], \"entity_id\": [\"T11\"]}}, \"Effect\": {\"text\": [[\"severe aplastic anemia (AA)\"]], \"start\": [[22]], \"entity_id\": [\"T8\"]}, \"Subject\": {\"text\": [[\"a case\"]], \"start\": [[12]], \"entity_id\": [\"T9\"]}, \"Speculated\": {\"text\": [[\"probably\"]], \"start\": [[59]], \"entity_id\": [\"T7\"], \"value\": true}}"
}
]
}
] |
3569037_4 | We present a case report of a patient with typhoid fever who experienced a hypersensitivity reaction subsequent to the infusion of chloramphenicol sodium succinate. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"subsequent to\"]], \"start\": [[101]], \"entity_id\": [\"T5\"]}, \"Subject\": {\"text\": [[\"a patient with typhoid fever\"]], \"start\": [[28]], \"entity_id\": [\"T3\"]}, \"Effect\": {\"text\": [[\"hypersensitivity reaction\"]], \"start\": [[75]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"the infusion of chloramphenicol sodium succinate\"]], \"start\": [[115]], \"entity_id\": [\"T6\"], \"Disorder\": {\"text\": [[\"typhoid fever\"]], \"start\": [[43]], \"entity_id\": [\"T7\"]}, \"Drug\": {\"text\": [[\"chloramphenicol sodium succinate\"]], \"start\": [[131]], \"entity_id\": [\"T8\"]}, \"Route\": {\"text\": [[\"infusion\"]], \"start\": [[119]], \"entity_id\": [\"T9\"]}}}"
}
]
}
] |
3310776_3 | This confirmed the history of captopril-related asthma. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"related\"]], \"start\": [[40]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"captopril\"]], \"start\": [[30]], \"entity_id\": [\"T3\"], \"Drug\": {\"text\": [[\"captopril\"]], \"start\": [[30]], \"entity_id\": [\"T6\"]}}, \"Effect\": {\"text\": [[\"asthma\"]], \"start\": [[48]], \"entity_id\": [\"T5\"]}}"
}
]
}
] |
9100429_3 | Four cases of adverse experiences with clonidine are described. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"with\"]], \"start\": [[34]], \"entity_id\": [\"T7\"]}, \"Subject\": {\"text\": [[\"Four cases\"]], \"start\": [[0]], \"entity_id\": [\"T4\"], \"Population\": {\"text\": [[\"Four\"]], \"start\": [[0]], \"entity_id\": [\"T8\"]}}, \"Treatment\": {\"text\": [[\"clonidine\"]], \"start\": [[39]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"clonidine\"]], \"start\": [[39]], \"entity_id\": [\"T9\"]}}, \"Effect\": {\"text\": [[\"adverse experiences\"]], \"start\": [[14]], \"entity_id\": [\"T6\"]}}"
}
]
}
] |
9972383_2 | OBJECTIVE: To report a case of reversible nonthrombocytopenic palpable purpura associated with metoclopramide. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"associated\"]], \"start\": [[79]], \"entity_id\": [\"T4\"]}, \"Effect\": {\"text\": [[\"reversible nonthrombocytopenic palpable purpura\"]], \"start\": [[31]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"metoclopramide\"]], \"start\": [[95]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"metoclopramide\"]], \"start\": [[95]], \"entity_id\": [\"T6\"]}}}"
}
]
}
] |
424824_6 | Three patients received respectively 190 mg, 175 mg, and 196 mg of methotrexate and developed bilateral pulmonary infiltrates without evidence of peripheral blood eosinophilia. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"developed\"]], \"start\": [[84]], \"entity_id\": [\"T5\"]}, \"Subject\": {\"text\": [[\"Three patients\"]], \"start\": [[0]], \"entity_id\": [\"T3\"], \"Population\": {\"text\": [[\"Three\"]], \"start\": [[0]], \"entity_id\": [\"T7\"]}}, \"Treatment\": {\"text\": [[\"received respectively 190 mg, 175 mg, and 196 mg of methotrexate\"]], \"start\": [[15]], \"entity_id\": [\"T4\"], \"Dosage\": {\"text\": [[\"190 mg\"], [\"175 mg\"], [\"196 mg\"]], \"start\": [[37], [45], [57]], \"entity_id\": [\"T8\", \"T9\", \"T10\"]}, \"Drug\": {\"text\": [[\"methotrexate\"]], \"start\": [[67]], \"entity_id\": [\"T11\"]}}, \"Effect\": {\"text\": [[\"bilateral pulmonary infiltrates without evidence of peripheral blood eosinophilia\"]], \"start\": [[94]], \"entity_id\": [\"T6\"]}}"
}
]
}
] |
9876812_1 | Clinicians should be aware of the possibility that vinorelbine may cause SIADH and possibly hypokalemia. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"cause\"]], \"start\": [[67]], \"entity_id\": [\"T8\"]}, \"Treatment\": {\"text\": [[\"vinorelbine\"]], \"start\": [[51]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"vinorelbine\"]], \"start\": [[51]], \"entity_id\": [\"T9\"]}}, \"Effect\": {\"text\": [[\"SIADH and possibly hypokalemia\"]], \"start\": [[73]], \"entity_id\": [\"T6\"]}, \"Speculated\": {\"text\": [[\"may\"]], \"start\": [[63]], \"entity_id\": [\"T7\"], \"value\": true}}"
}
]
}
] |
19995690_4 | We report a case of a 34-year-old man on carbamazepine for complex partial seizures who developed acute liver and renal failure on less than 2.5 grams a day of acetaminophen. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"on\"]], \"start\": [[38]], \"entity_id\": [\"T10\"]}, \"Treatment\": {\"text\": [[\"carbamazepine\", \"less than 2.5 grams a day of acetaminophen\"]], \"start\": [[41, 131]], \"entity_id\": [\"T11\"], \"Drug\": {\"text\": [[\"carbamazepine\"], [\"acetaminophen\"]], \"start\": [[41], [160]], \"entity_id\": [\"T16\", \"T20\"]}, \"Disorder\": {\"text\": [[\"complex partial seizures\"]], \"start\": [[59]], \"entity_id\": [\"T17\"]}, \"Dosage\": {\"text\": [[\"less than 2.5 grams\"]], \"start\": [[131]], \"entity_id\": [\"T18\"]}, \"Freq\": {\"text\": [[\"a day\"]], \"start\": [[151]], \"entity_id\": [\"T19\"]}, \"Combination\": [{\"event_id\": \"E2\", \"event_type\": \"Combination\", \"Trigger\": {\"text\": [[\"on\"]], \"start\": [[128]], \"entity_id\": [\"T21\"]}, \"Drug\": {\"text\": [[\"acetaminophen\"], [\"carbamazepine\"]], \"start\": [[160], [41]], \"entity_id\": [\"T20\", \"T16\"]}}]}, \"Effect\": {\"text\": [[\"acute liver and renal failure\"]], \"start\": [[98]], \"entity_id\": [\"T12\"]}, \"Subject\": {\"text\": [[\"a 34-year-old man\"]], \"start\": [[20]], \"entity_id\": [\"T13\"], \"Age\": {\"text\": [[\"34-year-old\"]], \"start\": [[22]], \"entity_id\": [\"T14\"]}, \"Gender\": {\"text\": [[\"man\"]], \"start\": [[34]], \"entity_id\": [\"T15\"]}}}"
}
]
}
] |
16935446_1 | Fever and maculopapular rashes appeared at 10 days after phenytoin initiation, and then the drug was discontinued. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"appeared\"]], \"start\": [[31]], \"entity_id\": [\"T7\"]}, \"Treatment\": {\"text\": [[\"phenytoin\"]], \"start\": [[57]], \"entity_id\": [\"T5\"], \"Time_elapsed\": {\"text\": [[\"10 days\"]], \"start\": [[43]], \"entity_id\": [\"T8\"]}, \"Drug\": {\"text\": [[\"phenytoin\"]], \"start\": [[57]], \"entity_id\": [\"T9\"]}}, \"Effect\": {\"text\": [[\"Fever and maculopapular rashes\"]], \"start\": [[0]], \"entity_id\": [\"T6\"]}}"
}
]
}
] |
15628319_4 | We report AZA-induced drug eruption that developed in two cases of systemic scleroderma with polymyositis. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[14]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"AZA\"]], \"start\": [[10]], \"entity_id\": [\"T3\"], \"Drug\": {\"text\": [[\"AZA\"]], \"start\": [[10]], \"entity_id\": [\"T7\"]}, \"Disorder\": {\"text\": [[\"systemic scleroderma with polymyositis\"]], \"start\": [[67]], \"entity_id\": [\"T1\"]}}, \"Effect\": {\"text\": [[\"drug eruption\"]], \"start\": [[22]], \"entity_id\": [\"T5\"]}, \"Subject\": {\"text\": [[\"two cases of systemic scleroderma with polymyositis\"]], \"start\": [[54]], \"entity_id\": [\"T8\"], \"Population\": {\"text\": [[\"two\"]], \"start\": [[54]], \"entity_id\": [\"T2\"]}}}"
}
]
}
] |
12776809_1 | Safety aspects of a coumarin-troxerutin combination regarding liver function in a double-blind placebo-controlled study. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"Safety aspects\"]], \"start\": [[0]], \"entity_id\": [\"T9\"]}, \"Treatment\": {\"text\": [[\"coumarin-troxerutin combination\"]], \"start\": [[20]], \"entity_id\": [\"T7\"], \"Drug\": {\"text\": [[\"coumarin\"], [\"troxerutin\"]], \"start\": [[20], [29]], \"entity_id\": [\"T10\", \"T11\"]}, \"Combination\": [{\"event_id\": \"E2\", \"event_type\": \"Combination\", \"Trigger\": {\"text\": [[\"combination\"]], \"start\": [[40]], \"entity_id\": [\"T12\"]}, \"Drug\": {\"text\": [[\"troxerutin\"], [\"coumarin\"]], \"start\": [[29], [20]], \"entity_id\": [\"T11\", \"T10\"]}}]}, \"Effect\": {\"text\": [[\"liver function\"]], \"start\": [[62]], \"entity_id\": [\"T8\"]}}"
}
]
}
] |
15580406_3 | Vogt-Koyanagi-Harada disease occurring during interferon alpha therapy for chronic hepatitis C. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"occurring\"]], \"start\": [[29]], \"entity_id\": [\"T4\"]}, \"Effect\": {\"text\": [[\"Vogt-Koyanagi-Harada disease\"]], \"start\": [[0]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"interferon alpha\"]], \"start\": [[46]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"interferon alpha\"]], \"start\": [[46]], \"entity_id\": [\"T7\"]}, \"Disorder\": {\"text\": [[\"chronic hepatitis C\"]], \"start\": [[75]], \"entity_id\": [\"T8\"]}}}"
}
]
}
] |
11206417_1 | Glucose and insulin exert additive ocular and renal vasodilator effects on healthy humans. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"exert\"]], \"start\": [[20]], \"entity_id\": [\"T11\"]}, \"Subject\": {\"text\": [[\"healthy humans\"]], \"start\": [[75]], \"entity_id\": [\"T9\"]}, \"Effect\": {\"text\": [[\"additive ocular and renal vasodilator effects\"]], \"start\": [[26]], \"entity_id\": [\"T10\"]}, \"Treatment\": {\"text\": [[\"Glucose and insulin\"]], \"start\": [[0]], \"entity_id\": [\"T12\"], \"Drug\": {\"text\": [[\"Glucose\"], [\"insulin\"]], \"start\": [[0], [12]], \"entity_id\": [\"T13\", \"T14\"]}, \"Combination\": [{\"event_id\": \"E2\", \"event_type\": \"Combination\", \"Trigger\": {\"text\": [[\"and\"]], \"start\": [[8]], \"entity_id\": [\"T15\"]}, \"Drug\": {\"text\": [[\"Glucose\"], [\"insulin\"]], \"start\": [[0], [12]], \"entity_id\": [\"T13\", \"T14\"]}}]}}"
}
]
}
] |
4025011_2 | Two patients with osteomyelitis who developed reversible cholestatic jaundice during treatment with oxacillin derivatives are described. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"developed\"]], \"start\": [[36]], \"entity_id\": [\"T5\"]}, \"Subject\": {\"text\": [[\"Two patients with osteomyelitis\"]], \"start\": [[0]], \"entity_id\": [\"T3\"], \"Population\": {\"text\": [[\"Two\"]], \"start\": [[0]], \"entity_id\": [\"T7\"]}}, \"Effect\": {\"text\": [[\"reversible cholestatic jaundice\"]], \"start\": [[46]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"oxacillin\"]], \"start\": [[100]], \"entity_id\": [\"T6\"], \"Disorder\": {\"text\": [[\"osteomyelitis\"]], \"start\": [[18]], \"entity_id\": [\"T8\"]}, \"Drug\": {\"text\": [[\"oxacillin\"]], \"start\": [[100]], \"entity_id\": [\"T9\"]}}}"
}
]
}
] |
1504404_3 | DATA SYNTHESIS: A 49-year-old man developed symptoms of severe psychosis concomitant with ciprofloxacin (250 mg bid) treatment. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"developed\"]], \"start\": [[34]], \"entity_id\": [\"T5\"]}, \"Subject\": {\"text\": [[\"A 49-year-old man\"]], \"start\": [[16]], \"entity_id\": [\"T3\"], \"Age\": {\"text\": [[\"49-year-old\"]], \"start\": [[18]], \"entity_id\": [\"T7\"]}, \"Gender\": {\"text\": [[\"man\"]], \"start\": [[30]], \"entity_id\": [\"T8\"]}}, \"Treatment\": {\"text\": [[\"ciprofloxacin\"]], \"start\": [[90]], \"entity_id\": [\"T4\"], \"Drug\": {\"text\": [[\"ciprofloxacin\"]], \"start\": [[90]], \"entity_id\": [\"T9\"]}, \"Dosage\": {\"text\": [[\"250 mg bid\"]], \"start\": [[105]], \"entity_id\": [\"T10\"]}}, \"Effect\": {\"text\": [[\"psychosis\"]], \"start\": [[63]], \"entity_id\": [\"T6\"]}, \"Severity\": {\"text\": [[\"severe\"]], \"start\": [[56]], \"entity_id\": [\"T11\"], \"value\": \"High\"}}"
}
]
}
] |
7673653_1 | Beneficial effect of low-dose mianserin on fluvoxamine-induced akathisia in an obsessive-compulsive patient. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[55]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"fluvoxamine\"]], \"start\": [[43]], \"entity_id\": [\"T4\"], \"Disorder\": {\"text\": [[\"obsessive-compulsive\"]], \"start\": [[79]], \"entity_id\": [\"T9\"]}, \"Drug\": {\"text\": [[\"fluvoxamine\"]], \"start\": [[43]], \"entity_id\": [\"T6\"]}}, \"Effect\": {\"text\": [[\"akathisia\"]], \"start\": [[63]], \"entity_id\": [\"T5\"]}, \"Subject\": {\"text\": [[\"obsessive-compulsive patient\"]], \"start\": [[79]], \"entity_id\": [\"T8\"]}}"
},
{
"event_id": "E2",
"event_type": "Potential_therapeutic_event",
"event_data": "{\"event_id\": \"E2\", \"event_type\": \"Potential_therapeutic_event\", \"Trigger\": {\"text\": [[\"Beneficial\"]], \"start\": [[0]], \"entity_id\": [\"T11\"]}, \"Subject\": {\"text\": [[\"obsessive-compulsive patient\"]], \"start\": [[79]], \"entity_id\": [\"T8\"]}, \"Treatment\": {\"text\": [[\"low-dose mianserin\"]], \"start\": [[21]], \"entity_id\": [\"T12\"], \"Disorder\": {\"text\": [[\"fluvoxamine-induced akathisia\"]], \"start\": [[43]], \"entity_id\": [\"T10\"]}, \"Dosage\": {\"text\": [[\"low-dose\"]], \"start\": [[21]], \"entity_id\": [\"T13\"]}, \"Drug\": {\"text\": [[\"mianserin\"]], \"start\": [[30]], \"entity_id\": [\"T14\"]}}}"
}
]
}
] |
8862924_3 | Potential causes of methamphetamine-related keratitis can be divided into four categories resulting from (a) direct pharmacologic and physical effects of methamphetamine; (b) the toxic effects of diluting or "cutting" agents such as lidocaine and quinine; (c) effects related to the route of drug administration (intravenous, inhalation, smoking); and (d) manufacture-related effects of exposure to unintentional caustic contaminants in the final product. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"related\"]], \"start\": [[36]], \"entity_id\": [\"T9\"]}, \"Treatment\": {\"text\": [[\"methamphetamine\"]], \"start\": [[20]], \"entity_id\": [\"T10\"], \"Drug\": {\"text\": [[\"methamphetamine\"]], \"start\": [[20]], \"entity_id\": [\"T12\"]}}, \"Effect\": {\"text\": [[\"keratitis\"]], \"start\": [[44]], \"entity_id\": [\"T11\"]}}"
}
]
}
] |
2028358_2 | Pulmonary oedema after hexoprenaline administration in preterm labour. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"after\"]], \"start\": [[17]], \"entity_id\": [\"T6\"]}, \"Effect\": {\"text\": [[\"Pulmonary oedema\"]], \"start\": [[0]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"hexoprenaline\"]], \"start\": [[23]], \"entity_id\": [\"T4\"], \"Disorder\": {\"text\": [[\"preterm labour\"]], \"start\": [[55]], \"entity_id\": [\"T5\"]}, \"Drug\": {\"text\": [[\"hexoprenaline\"]], \"start\": [[23]], \"entity_id\": [\"T7\"]}}}"
}
]
}
] |
11144696_10 | Venlafaxine-associated seizures at therapeutic doses have not been reported in the literature. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"associated\"]], \"start\": [[12]], \"entity_id\": [\"T6\"]}, \"Treatment\": {\"text\": [[\"Venlafaxine\"]], \"start\": [[0]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"Venlafaxine\"]], \"start\": [[0]], \"entity_id\": [\"T9\"]}}, \"Effect\": {\"text\": [[\"seizures\"]], \"start\": [[23]], \"entity_id\": [\"T7\"]}, \"Negated\": {\"text\": [[\"not\"]], \"start\": [[58]], \"entity_id\": [\"T8\"], \"value\": true}}"
}
]
}
] |
9184269_2 | Methotrexate-induced pneumonitis in patients with rheumatoid arthritis and psoriatic arthritis: report of five cases and review of the literature. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[13]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"Methotrexate\"]], \"start\": [[0]], \"entity_id\": [\"T3\"], \"Disorder\": {\"text\": [[\"rheumatoid arthritis\"], [\"psoriatic arthritis\"]], \"start\": [[50], [75]], \"entity_id\": [\"T7\", \"T8\"]}, \"Drug\": {\"text\": [[\"Methotrexate\"]], \"start\": [[0]], \"entity_id\": [\"T9\"]}}, \"Effect\": {\"text\": [[\"pneumonitis\"]], \"start\": [[21]], \"entity_id\": [\"T5\"]}, \"Subject\": {\"text\": [[\"patients with rheumatoid arthritis and psoriatic arthritis\"]], \"start\": [[36]], \"entity_id\": [\"T6\"]}}"
}
]
}
] |
3677571_4 | She was receiving phenytoin sodium 300 mg/day; carbamazepine 200 mg four times daily had been discontinued four days before admission because of leukopenia. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"because\"]], \"start\": [[134]], \"entity_id\": [\"T9\"]}, \"Effect\": {\"text\": [[\"leukopenia\"]], \"start\": [[145]], \"entity_id\": [\"T7\"]}, \"Treatment\": {\"text\": [[\"carbamazepine 200 mg four times daily\"]], \"start\": [[47]], \"entity_id\": [\"T8\"], \"Drug\": {\"text\": [[\"carbamazepine\"]], \"start\": [[47]], \"entity_id\": [\"T10\"]}, \"Dosage\": {\"text\": [[\"200 mg\"]], \"start\": [[61]], \"entity_id\": [\"T11\"]}, \"Freq\": {\"text\": [[\"four times daily\"]], \"start\": [[68]], \"entity_id\": [\"T12\"]}}}"
}
]
}
] |
9211543_4 | Thoracoscopic biopsy to confirm metastasis revealed instead fibrotic lesions apparently attributable to bleomycin or cyclophosphamide. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"attributable\"]], \"start\": [[88]], \"entity_id\": [\"T7\"]}, \"Effect\": {\"text\": [[\"fibrotic lesions\"]], \"start\": [[60]], \"entity_id\": [\"T6\"]}, \"Treatment\": {\"text\": [[\"bleomycin or cyclophosphamide\"]], \"start\": [[104]], \"entity_id\": [\"T8\"], \"Drug\": {\"text\": [[\"bleomycin\"], [\"cyclophosphamide\"]], \"start\": [[104], [117]], \"entity_id\": [\"T9\", \"T10\"]}}, \"Speculated\": {\"text\": [[\"apparently\"]], \"start\": [[77]], \"entity_id\": [\"T11\"], \"value\": true}}"
}
]
}
] |
16968538_4 | We present a case of hemolytic-uremic syndrome that developed during the 4th cycle of combination chemotherapy with oxaliplatin, 5-fluorouracil and leucovorin. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"developed\"]], \"start\": [[52]], \"entity_id\": [\"T8\"]}, \"Effect\": {\"text\": [[\"hemolytic-uremic syndrome\"]], \"start\": [[21]], \"entity_id\": [\"T7\"]}, \"Treatment\": {\"text\": [[\"during the 4th cycle of combination chemotherapy with oxaliplatin, 5-fluorouracil and leucovorin\"]], \"start\": [[62]], \"entity_id\": [\"T9\"], \"Drug\": {\"text\": [[\"oxaliplatin\"], [\"fluorouracil\"], [\"leucovorin\"]], \"start\": [[116], [131], [148]], \"entity_id\": [\"T10\", \"T11\", \"T12\"]}}}"
}
]
}
] |
16632429_1 | We report the case of a lung cancer patient with bronquiloalveolar carcinoma (BAC) presenting with BOOP after chemotherapy with docetaxel and gemcitabine producing severe respiratory insufficiency, and simulating a progression of the tumor. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"after\"]], \"start\": [[104]], \"entity_id\": [\"T14\"]}, \"Subject\": {\"text\": [[\"lung cancer patient with bronquiloalveolar carcinoma (BAC)\"]], \"start\": [[24]], \"entity_id\": [\"T10\"]}, \"Effect\": {\"text\": [[\"producing severe respiratory insufficiency, and simulating a progression of the tumor\", \"BOOP\"]], \"start\": [[154, 99]], \"entity_id\": [\"T11\"]}, \"Treatment\": {\"text\": [[\"chemotherapy with docetaxel and gemcitabine\"]], \"start\": [[110]], \"entity_id\": [\"T12\"], \"Disorder\": {\"text\": [[\"lung cancer\"], [\"bronquiloalveolar carcinoma (BAC)\"]], \"start\": [[24], [49]], \"entity_id\": [\"T15\", \"T19\"]}, \"Drug\": {\"text\": [[\"docetaxel\"], [\"gemcitabine\"]], \"start\": [[128], [142]], \"entity_id\": [\"T16\", \"T17\"]}, \"Route\": {\"text\": [[\"chemotherapy\"]], \"start\": [[110]], \"entity_id\": [\"T1\"]}, \"Combination\": [{\"event_id\": \"E2\", \"event_type\": \"Combination\", \"Trigger\": {\"text\": [[\"and\"]], \"start\": [[138]], \"entity_id\": [\"T18\"]}, \"Drug\": {\"text\": [[\"docetaxel\"], [\"gemcitabine\"]], \"start\": [[128], [142]], \"entity_id\": [\"T16\", \"T17\"]}}]}}"
}
]
}
] |
9240497_1 | Relapse in the external auditory canal of acute promyelocytic leukemia after treatment with all-trans retinoic acid. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"after\"]], \"start\": [[71]], \"entity_id\": [\"T4\"]}, \"Effect\": {\"text\": [[\"Relapse in the external auditory canal of acute promyelocytic leukemia\"]], \"start\": [[0]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"treatment with all-trans retinoic acid\"]], \"start\": [[77]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"all-trans retinoic acid\"]], \"start\": [[92]], \"entity_id\": [\"T6\"]}}}"
}
]
}
] |
10439378_1 | Acute neutrophilic dermatosis induced by all-trans-retinoic acid treatment for acute promyelocytic leukemia. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced by\"]], \"start\": [[30]], \"entity_id\": [\"T3\"]}, \"Effect\": {\"text\": [[\"Acute neutrophilic dermatosis\"]], \"start\": [[0]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"all-trans-retinoic acid\"]], \"start\": [[41]], \"entity_id\": [\"T6\"], \"Disorder\": {\"text\": [[\"acute promyelocytic leukemia\"]], \"start\": [[79]], \"entity_id\": [\"T4\"]}, \"Drug\": {\"text\": [[\"all-trans-retinoic acid\"]], \"start\": [[41]], \"entity_id\": [\"T7\"]}}}"
}
]
}
] |
15840734_1 | Fluphenazine-induced neuroleptic malignant syndrome in a schizophrenic patient. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[13]], \"entity_id\": [\"T7\"]}, \"Treatment\": {\"text\": [[\"Fluphenazine\"]], \"start\": [[0]], \"entity_id\": [\"T6\"], \"Drug\": {\"text\": [[\"Fluphenazine\"]], \"start\": [[0]], \"entity_id\": [\"T11\"]}, \"Disorder\": {\"text\": [[\"schizophrenic\"]], \"start\": [[57]], \"entity_id\": [\"T12\"]}}, \"Effect\": {\"text\": [[\"neuroleptic malignant syndrome\"]], \"start\": [[21]], \"entity_id\": [\"T8\"]}, \"Subject\": {\"text\": [[\"a schizophrenic patient\"]], \"start\": [[55]], \"entity_id\": [\"T9\"]}}"
}
]
}
] |
19039026_1 | Biopsy-proven acute interstitial nephritis associated with the tyrosine kinase inhibitor sunitinib: a class effect? | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"associated\"]], \"start\": [[43]], \"entity_id\": [\"T3\"]}, \"Effect\": {\"text\": [[\"acute interstitial nephritis\"]], \"start\": [[14]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"tyrosine kinase inhibitor sunitinib\"]], \"start\": [[63]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"sunitinib\"]], \"start\": [[89]], \"entity_id\": [\"T6\"]}}}"
}
]
}
] |
8222875_4 | We describe two women who developed HUS after MMC therapy and presented massive pulmonary bleeding. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"after\"]], \"start\": [[40]], \"entity_id\": [\"T7\"]}, \"Subject\": {\"text\": [[\"two women\"]], \"start\": [[12]], \"entity_id\": [\"T5\"], \"Population\": {\"text\": [[\"two\"]], \"start\": [[12]], \"entity_id\": [\"T9\"]}, \"Gender\": {\"text\": [[\"women\"]], \"start\": [[16]], \"entity_id\": [\"T10\"]}}, \"Effect\": {\"text\": [[\"HUS\", \"massive pulmonary bleeding\"]], \"start\": [[36, 72]], \"entity_id\": [\"T6\"]}, \"Treatment\": {\"text\": [[\"MMC\"]], \"start\": [[46]], \"entity_id\": [\"T8\"], \"Drug\": {\"text\": [[\"MMC\"]], \"start\": [[46]], \"entity_id\": [\"T11\"]}}, \"Severity\": {\"text\": [[\"massive\"]], \"start\": [[72]], \"entity_id\": [\"T12\"], \"value\": \"High\"}}"
}
]
}
] |
6529939_2 | Alternating sinus rhythm and intermittent sinoatrial (S-A) block was observed in a 57-year-old woman, under treatment for angina with 80 mg propranolol daily. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"treatment\"]], \"start\": [[108]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"80 mg propranolol daily.\"]], \"start\": [[134]], \"entity_id\": [\"T6\"], \"Dosage\": {\"text\": [[\"80 mg\"]], \"start\": [[134]], \"entity_id\": [\"T11\"]}, \"Drug\": {\"text\": [[\"propranolol\"]], \"start\": [[140]], \"entity_id\": [\"T12\"]}, \"Freq\": {\"text\": [[\"daily\"]], \"start\": [[152]], \"entity_id\": [\"T13\"]}, \"Disorder\": {\"text\": [[\"angina\"]], \"start\": [[122]], \"entity_id\": [\"T14\"]}}, \"Subject\": {\"text\": [[\"a 57-year-old woman\"]], \"start\": [[81]], \"entity_id\": [\"T7\"], \"Age\": {\"text\": [[\"57-year-old\"]], \"start\": [[83]], \"entity_id\": [\"T9\"]}, \"Gender\": {\"text\": [[\"woman\"]], \"start\": [[95]], \"entity_id\": [\"T10\"]}}, \"Effect\": {\"text\": [[\"Alternating sinus rhythm and intermittent sinoatrial (S-A) block\"]], \"start\": [[0]], \"entity_id\": [\"T8\"]}}"
}
]
}
] |
9399776_4 | These case reports provide evidence that 5-aminosalicylic acid may induce acute pancreatitis after long term treatment. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induce\"]], \"start\": [[67]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"5-aminosalicylic acid\"]], \"start\": [[41]], \"entity_id\": [\"T3\"], \"Drug\": {\"text\": [[\"5-aminosalicylic acid\"]], \"start\": [[41]], \"entity_id\": [\"T6\"]}, \"Duration\": {\"text\": [[\"long term\"]], \"start\": [[99]], \"entity_id\": [\"T7\"]}}, \"Effect\": {\"text\": [[\"acute pancreatitis\"]], \"start\": [[74]], \"entity_id\": [\"T5\"]}}"
}
]
}
] |
17896898_4 | During that time, he had also been taking amphetamine-dextroamphetamine (Adderall) on work days for his ADHD. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Potential_therapeutic_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Potential_therapeutic_event\", \"Trigger\": {\"text\": [[\"taking\"]], \"start\": [[35]], \"entity_id\": [\"T6\"]}, \"Treatment\": {\"text\": [[\"amphetamine-dextroamphetamine (Adderall)\"]], \"start\": [[42]], \"entity_id\": [\"T8\"], \"Disorder\": {\"text\": [[\"ADHD\"]], \"start\": [[104]], \"entity_id\": [\"T7\"]}, \"Drug\": {\"text\": [[\"amphetamine-dextroamphetamine\"]], \"start\": [[42]], \"entity_id\": [\"T11\"]}}, \"Subject\": {\"text\": [[\"he\"]], \"start\": [[18]], \"entity_id\": [\"T9\"], \"Gender\": {\"text\": [[\"he\"]], \"start\": [[18]], \"entity_id\": [\"T10\"]}}}"
}
]
}
] |
9375469_2 | Therefore, we diagnosed her eruption as contact dermatitis due to sodium bisulfite. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"diagnosed\"]], \"start\": [[14]], \"entity_id\": [\"T7\"]}, \"Treatment\": {\"text\": [[\"sodium bisulfite\"]], \"start\": [[66]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"sodium bisulfite\"]], \"start\": [[66]], \"entity_id\": [\"T8\"]}}, \"Effect\": {\"text\": [[\"r eruption as contact dermatitis\"]], \"start\": [[26]], \"entity_id\": [\"T6\"]}}"
}
]
}
] |
3485422_1 | Macular infarction after endophthalmitis treated with vitrectomy and intravitreal gentamicin. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"after\"]], \"start\": [[19]], \"entity_id\": [\"T6\"]}, \"Effect\": {\"text\": [[\"Macular infarction\"]], \"start\": [[0]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"endophthalmitis treated with vitrectomy and intravitreal gentamicin\"]], \"start\": [[25]], \"entity_id\": [\"T3\"], \"Disorder\": {\"text\": [[\"endophthalmitis\"]], \"start\": [[25]], \"entity_id\": [\"T5\"]}, \"Route\": {\"text\": [[\"vitrectomy and intravitreal\"]], \"start\": [[54]], \"entity_id\": [\"T7\"]}, \"Drug\": {\"text\": [[\"gentamicin\"]], \"start\": [[82]], \"entity_id\": [\"T8\"]}}}"
}
]
}
] |
11876387_2 | Since tamoxifen therapy can induce endometrial disorders, surveillance schemes of women taking tamoxifen have been recommended. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induce\"]], \"start\": [[28]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"tamoxifen therapy\"]], \"start\": [[6]], \"entity_id\": [\"T4\"], \"Drug\": {\"text\": [[\"tamoxifen\"]], \"start\": [[6]], \"entity_id\": [\"T10\"]}}, \"Effect\": {\"text\": [[\"endometrial disorders\"]], \"start\": [[35]], \"entity_id\": [\"T6\"]}, \"Subject\": {\"text\": [[\"women\"]], \"start\": [[82]], \"entity_id\": [\"T7\"], \"Gender\": {\"text\": [[\"women\"]], \"start\": [[82]], \"entity_id\": [\"T8\"]}}}"
}
]
}
] |
11837564_2 | Warfarin-associated bleeding complication saved life. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"associated\"]], \"start\": [[9]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"Warfarin\"]], \"start\": [[0]], \"entity_id\": [\"T3\"], \"Drug\": {\"text\": [[\"Warfarin\"]], \"start\": [[0]], \"entity_id\": [\"T6\"]}}, \"Effect\": {\"text\": [[\"bleeding complication saved life\"]], \"start\": [[20]], \"entity_id\": [\"T5\"]}}"
}
]
}
] |
8979664_1 | METHODS/RESULTS: This paper presents a new case of rifabutin uveitis and a review of the various published reports to date. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"presents\"]], \"start\": [[28]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"rifabutin\"]], \"start\": [[51]], \"entity_id\": [\"T3\"], \"Drug\": {\"text\": [[\"rifabutin\"]], \"start\": [[51]], \"entity_id\": [\"T6\"]}}, \"Effect\": {\"text\": [[\"uveitis\"]], \"start\": [[61]], \"entity_id\": [\"T4\"]}, \"Subject\": {\"text\": [[\"new case\"]], \"start\": [[39]], \"entity_id\": [\"T7\"]}}"
}
]
}
] |
12860350_1 | Acute abdomen due to endometriosis in a premenopausal woman taking tamoxifen. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"taking\"]], \"start\": [[60]], \"entity_id\": [\"T7\"]}, \"Effect\": {\"text\": [[\"Acute abdomen due to endometriosis\"]], \"start\": [[0]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"tamoxifen\"]], \"start\": [[67]], \"entity_id\": [\"T6\"], \"Drug\": {\"text\": [[\"tamoxifen\"]], \"start\": [[67]], \"entity_id\": [\"T8\"]}}}"
}
]
}
] |
18094347_3 | DISCUSSION: Methotrexate-induced papular eruption is rarely reported shortly after beginning methotrexate therapy in patients with acute exacerbation of collagen vascular diseases. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[25]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"Methotrexate\"]], \"start\": [[12]], \"entity_id\": [\"T3\"], \"Drug\": {\"text\": [[\"Methotrexate\"]], \"start\": [[12]], \"entity_id\": [\"T9\"]}, \"Time_elapsed\": {\"text\": [[\"shortly after\"]], \"start\": [[69]], \"entity_id\": [\"T11\"]}}, \"Effect\": {\"text\": [[\"papular eruption\"]], \"start\": [[33]], \"entity_id\": [\"T5\"]}, \"Subject\": {\"text\": [[\"patients with acute exacerbation of collagen vascular diseases\"]], \"start\": [[117]], \"entity_id\": [\"T6\"], \"Disorder\": {\"text\": [[\"acute exacerbation of collagen vascular diseases\"]], \"start\": [[131]], \"entity_id\": [\"T8\"]}}}"
}
]
}
] |
15028964_5 | We describe 3 patients on concomitant amiodarone and warfarin who developed amiodarone-induced thyrotoxicosis heralded by a significant decrease in warfarin requirements. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"developed\"]], \"start\": [[66]], \"entity_id\": [\"T12\"]}, \"Effect\": {\"text\": [[\"amiodarone-induced thyrotoxicosis\"]], \"start\": [[76]], \"entity_id\": [\"T23\"]}, \"Subject\": {\"text\": [[\"3 patients\"]], \"start\": [[12]], \"entity_id\": [\"T10\"], \"Population\": {\"text\": [[\"3\"]], \"start\": [[12]], \"entity_id\": [\"T14\"]}}, \"Treatment\": {\"text\": [[\"concomitant amiodarone and warfarin\"]], \"start\": [[26]], \"entity_id\": [\"T11\"], \"Drug\": {\"text\": [[\"amiodarone\"], [\"warfarin\"]], \"start\": [[38], [53]], \"entity_id\": [\"T18\", \"T19\"]}, \"Combination\": [{\"event_id\": \"E2\", \"event_type\": \"Combination\", \"Trigger\": {\"text\": [[\"concomitant\"]], \"start\": [[26]], \"entity_id\": [\"T17\"]}, \"Drug\": {\"text\": [[\"amiodarone\"], [\"warfarin\"]], \"start\": [[38], [53]], \"entity_id\": [\"T18\", \"T19\"]}}]}}"
},
{
"event_id": "E3",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E3\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[87]], \"entity_id\": [\"T21\"]}, \"Treatment\": {\"text\": [[\"amiodarone\"]], \"start\": [[76]], \"entity_id\": [\"T13\"], \"Drug\": {\"text\": [[\"amiodarone\"]], \"start\": [[76]], \"entity_id\": [\"T22\"]}}, \"Effect\": {\"text\": [[\"thyrotoxicosis\"]], \"start\": [[95]], \"entity_id\": [\"T15\"]}}"
}
]
}
] |
25157214_3 | The aim of this post-hoc analysis of data from a Phase III clinical trial (VISTA; NCT00298831) was to investigate the impact of antibiotics on recovery from rocuronium-induced NMB after administration of sugammadex for reversal, and compared the neuromuscular recovery in patients who received antibiotics preoperatively with those who did not. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[168]], \"entity_id\": [\"T9\"]}, \"Treatment\": {\"text\": [[\"rocuronium\"]], \"start\": [[157]], \"entity_id\": [\"T8\"], \"Drug\": {\"text\": [[\"rocuronium\"]], \"start\": [[157]], \"entity_id\": [\"T11\"]}}, \"Effect\": {\"text\": [[\"NMB\"]], \"start\": [[176]], \"entity_id\": [\"T10\"]}}"
},
{
"event_id": "E2",
"event_type": "Potential_therapeutic_event",
"event_data": "{\"event_id\": \"E2\", \"event_type\": \"Potential_therapeutic_event\", \"Trigger\": {\"text\": [[\"recovery\"]], \"start\": [[143]], \"entity_id\": [\"T15\"]}, \"Treatment\": {\"text\": [[\"antibiotics\"]], \"start\": [[128]], \"entity_id\": [\"T13\"], \"Disorder\": {\"text\": [[\"rocuronium-induced NMB\"]], \"start\": [[157]], \"entity_id\": [\"T16\"]}, \"Drug\": {\"text\": [[\"antibiotics\"]], \"start\": [[128]], \"entity_id\": [\"T14\"]}}}"
}
]
}
] |
14693027_1 | All patients had taken phenytoin for variable time periods (range 16-80 days; mean: 40) and were on the medication when the skin lesions first appeared. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"appeared\"]], \"start\": [[143]], \"entity_id\": [\"T6\"]}, \"Treatment\": {\"text\": [[\"phenytoin for variable time periods (range 16-80 days; mean: 40)\"]], \"start\": [[23]], \"entity_id\": [\"T3\"], \"Drug\": {\"text\": [[\"phenytoin\"]], \"start\": [[23]], \"entity_id\": [\"T7\"]}, \"Duration\": {\"text\": [[\"16-80 days;\"], [\"40\"]], \"start\": [[66], [84]], \"entity_id\": [\"T8\", \"T9\"]}}, \"Subject\": {\"text\": [[\"All patients\"]], \"start\": [[0]], \"entity_id\": [\"T4\"]}, \"Effect\": {\"text\": [[\"skin lesions\"]], \"start\": [[124]], \"entity_id\": [\"T5\"]}}"
}
]
}
] |
9754850_3 | One should therefore be aware of possible extrapyramidal side effects with olanzapine that are reduced compared to classical neuroleptic drugs but not completely eliminated. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"with\"]], \"start\": [[70]], \"entity_id\": [\"T4\"]}, \"Effect\": {\"text\": [[\"extrapyramidal side effects\"]], \"start\": [[42]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"olanzapine\"]], \"start\": [[75]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"olanzapine\"]], \"start\": [[75]], \"entity_id\": [\"T6\"]}}, \"Speculated\": {\"text\": [[\"possible\"]], \"start\": [[33]], \"entity_id\": [\"T7\"], \"value\": true}}"
}
]
}
] |
122410_1 | A patient who had been treated with large doses of thyroid hormone for several years developed features of secondary hypothyroidism after thyroid hormone withdrawal. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"developed\"]], \"start\": [[85]], \"entity_id\": [\"T6\"]}, \"Subject\": {\"text\": [[\"A patient\"]], \"start\": [[0]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"thyroid hormone withdrawal\"]], \"start\": [[138]], \"entity_id\": [\"T4\"], \"Drug\": {\"text\": [[\"thyroid hormone\"]], \"start\": [[138]], \"entity_id\": [\"T7\"]}}, \"Effect\": {\"text\": [[\"secondary hypothyroidism\"]], \"start\": [[107]], \"entity_id\": [\"T5\"]}}"
}
]
}
] |
18344455_5 | This article discusses the possibility that simultaneous use of valproic acid, lamotrigine, and phenytoin could give this combination of toxicities and that concurrent viral infection may increase this risk. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"give\"]], \"start\": [[112]], \"entity_id\": [\"T11\"]}, \"Treatment\": {\"text\": [[\"valproic acid, lamotrigine, and phenytoin\"]], \"start\": [[64]], \"entity_id\": [\"T9\"], \"Drug\": {\"text\": [[\"valproic acid\"], [\"lamotrigine\"], [\"phenytoin\"]], \"start\": [[64], [79], [96]], \"entity_id\": [\"T12\", \"T13\", \"T14\"]}, \"Combination\": [{\"event_id\": \"E2\", \"event_type\": \"Combination\", \"Trigger\": {\"text\": [[\"simultaneous\"]], \"start\": [[44]], \"entity_id\": [\"T15\"]}, \"Drug\": {\"text\": [[\"valproic acid\"], [\"lamotrigine\"], [\"phenytoin\"]], \"start\": [[64], [79], [96]], \"entity_id\": [\"T12\", \"T13\", \"T14\"]}}]}, \"Effect\": {\"text\": [[\"toxicities\", \"concurrent viral infection\"]], \"start\": [[137, 157]], \"entity_id\": [\"T10\"]}, \"Speculated\": {\"text\": [[\"possibility\"]], \"start\": [[27]], \"entity_id\": [\"T16\"], \"value\": true}}"
}
]
}
] |
984862_2 | A second patient with a similar glucose tolerance test result showed postprandial hyperglycemia when treated similarly with betamethasone valerate cream 0.1%. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"showed\"]], \"start\": [[62]], \"entity_id\": [\"T3\"]}, \"Effect\": {\"text\": [[\"postprandial hyperglycemia\"]], \"start\": [[69]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"betamethasone valerate cream 0.1%\"]], \"start\": [[124]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"betamethasone valerate\"]], \"start\": [[124]], \"entity_id\": [\"T6\"]}, \"Route\": {\"text\": [[\"cream\"]], \"start\": [[147]], \"entity_id\": [\"T7\"]}}}"
}
]
}
] |
3677571_1 | Phenytoin-induced hypersensitivity reactions. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[10]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"Phenytoin\"]], \"start\": [[0]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"Phenytoin\"]], \"start\": [[0]], \"entity_id\": [\"T7\"]}}, \"Effect\": {\"text\": [[\"hypersensitivity reactions.\"]], \"start\": [[18]], \"entity_id\": [\"T6\"]}}"
}
]
}
] |
9545161_1 | A 54-year-old man developed TEN 4 weeks after beginning lamotrigine for complex partial seizures related to a glioblastoma multiforme brain tumor. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"developed\"]], \"start\": [[18]], \"entity_id\": [\"T6\"]}, \"Subject\": {\"text\": [[\"A 54-year-old man\", \"complex partial seizures related to a glioblastoma multiforme brain tumor\"]], \"start\": [[0, 72]], \"entity_id\": [\"T3\"], \"Age\": {\"text\": [[\"54-year-old\"]], \"start\": [[2]], \"entity_id\": [\"T7\"]}, \"Gender\": {\"text\": [[\"man\"]], \"start\": [[14]], \"entity_id\": [\"T8\"]}, \"Disorder\": {\"text\": [[\"glioblastoma multiforme brain tumor\"]], \"start\": [[110]], \"entity_id\": [\"T12\"]}}, \"Effect\": {\"text\": [[\"TEN\"]], \"start\": [[28]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"4 weeks after beginning lamotrigine\"]], \"start\": [[32]], \"entity_id\": [\"T5\"], \"Time_elapsed\": {\"text\": [[\"4 weeks\"]], \"start\": [[32]], \"entity_id\": [\"T9\"]}, \"Drug\": {\"text\": [[\"lamotrigine\"]], \"start\": [[56]], \"entity_id\": [\"T10\"]}, \"Disorder\": {\"text\": [[\"complex partial seizures\"]], \"start\": [[72]], \"entity_id\": [\"T11\"]}}}"
}
]
}
] |
11881322_5 | The occurrence of acute hepatitis is best known for ketoconazole. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"for\"]], \"start\": [[48]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"ketoconazole\"]], \"start\": [[52]], \"entity_id\": [\"T3\"], \"Drug\": {\"text\": [[\"ketoconazole\"]], \"start\": [[52]], \"entity_id\": [\"T6\"]}}, \"Effect\": {\"text\": [[\"acute hepatitis\"]], \"start\": [[18]], \"entity_id\": [\"T4\"]}}"
}
]
}
] |
6233326_2 | Optic neuropathy developed in a patient with rheumatoid arthritis who had been receiving D-penicillamine for about 1 year. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"developed\"]], \"start\": [[17]], \"entity_id\": [\"T4\"]}, \"Effect\": {\"text\": [[\"Optic neuropathy\"]], \"start\": [[0]], \"entity_id\": [\"T3\"]}, \"Subject\": {\"text\": [[\"a patient with rheumatoid arthritis\"]], \"start\": [[30]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"D-penicillamine for about 1 year\"]], \"start\": [[89]], \"entity_id\": [\"T6\"], \"Disorder\": {\"text\": [[\"rheumatoid arthritis\"]], \"start\": [[45]], \"entity_id\": [\"T7\"]}, \"Drug\": {\"text\": [[\"D-penicillamine\"]], \"start\": [[89]], \"entity_id\": [\"T8\"]}, \"Duration\": {\"text\": [[\"1 year\"]], \"start\": [[115]], \"entity_id\": [\"T9\"]}}}"
}
]
}
] |
19520277_1 | Stupor and fast activity on electroencephalography in a child treated with valproate. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"with\"]], \"start\": [[70]], \"entity_id\": [\"T6\"]}, \"Subject\": {\"text\": [[\"a child\"]], \"start\": [[54]], \"entity_id\": [\"T3\"], \"Age\": {\"text\": [[\"child\"]], \"start\": [[56]], \"entity_id\": [\"T7\"]}}, \"Treatment\": {\"text\": [[\"valproate\"]], \"start\": [[75]], \"entity_id\": [\"T4\"], \"Drug\": {\"text\": [[\"valproate\"]], \"start\": [[75]], \"entity_id\": [\"T8\"]}}, \"Effect\": {\"text\": [[\"Stupor\", \"fast activity on electroencephalography\"]], \"start\": [[0, 11]], \"entity_id\": [\"T5\"]}}"
}
]
}
] |
7606071_5 | During her third cycle, she again received cisplatin 100 mg/m2 over 30 minutes and developed palmar pruritus, urticaria, and edema. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"developed\"]], \"start\": [[83]], \"entity_id\": [\"T11\"]}, \"Treatment\": {\"text\": [[\"cisplatin 100 mg/m2 over 30 minutes\"]], \"start\": [[43]], \"entity_id\": [\"T9\"], \"Time_elapsed\": {\"text\": [[\"30 minutes\"]], \"start\": [[68]], \"entity_id\": [\"T14\"]}, \"Dosage\": {\"text\": [[\"100 mg/m2\"]], \"start\": [[53]], \"entity_id\": [\"T15\"]}, \"Drug\": {\"text\": [[\"cisplatin\"]], \"start\": [[43]], \"entity_id\": [\"T16\"]}}, \"Subject\": {\"text\": [[\"she\"]], \"start\": [[24]], \"entity_id\": [\"T10\"], \"Gender\": {\"text\": [[\"she\"]], \"start\": [[24]], \"entity_id\": [\"T13\"]}}, \"Effect\": {\"text\": [[\"palmar pruritus, urticaria, and edema\"]], \"start\": [[93]], \"entity_id\": [\"T12\"]}}"
}
]
}
] |
9169264_3 | The case of a patient with infectious mononucleosis treated with cephalexin who later showed a rash is presented and the previous literature is reviewed. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"showed\"]], \"start\": [[86]], \"entity_id\": [\"T6\"]}, \"Treatment\": {\"text\": [[\"cephalexin\"]], \"start\": [[65]], \"entity_id\": [\"T3\"], \"Drug\": {\"text\": [[\"cephalexin\"]], \"start\": [[65]], \"entity_id\": [\"T8\"]}, \"Disorder\": {\"text\": [[\"infectious mononucleosis\"]], \"start\": [[27]], \"entity_id\": [\"T9\"]}}, \"Effect\": {\"text\": [[\"rash\"]], \"start\": [[95]], \"entity_id\": [\"T4\"]}, \"Subject\": {\"text\": [[\"a patient with infectious mononucleosis\"]], \"start\": [[12]], \"entity_id\": [\"T5\"]}}"
}
]
}
] |
9855339_1 | After 1 week of nefazodone therapy the patient experienced headache, confusion, and "gray areas" in her vision, without abnormal ophthalmologic findings. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"experienced\"]], \"start\": [[47]], \"entity_id\": [\"T10\"]}, \"Effect\": {\"text\": [[\"headache, confusion, and \\\"gray areas\\\" in her vision, without abnormal ophthalmologic findings\"]], \"start\": [[59]], \"entity_id\": [\"T7\"]}, \"Subject\": {\"text\": [[\"patient\", \"her\"]], \"start\": [[39, 100]], \"entity_id\": [\"T8\"], \"Gender\": {\"text\": [[\"her\"]], \"start\": [[100]], \"entity_id\": [\"T11\"]}}, \"Treatment\": {\"text\": [[\"After 1 week of nefazodone therapy\"]], \"start\": [[0]], \"entity_id\": [\"T9\"], \"Time_elapsed\": {\"text\": [[\"1 week\"]], \"start\": [[6]], \"entity_id\": [\"T12\"]}, \"Drug\": {\"text\": [[\"nefazodone\"]], \"start\": [[16]], \"entity_id\": [\"T13\"]}}}"
}
]
}
] |
8771575_4 | Nitrofurantoin-induced pulmonary toxicity during pregnancy: a report of a case and review of the literature. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[15]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"Nitrofurantoin\"]], \"start\": [[0]], \"entity_id\": [\"T3\"], \"Drug\": {\"text\": [[\"Nitrofurantoin\"]], \"start\": [[0]], \"entity_id\": [\"T6\"]}}, \"Effect\": {\"text\": [[\"pulmonary toxicity\"]], \"start\": [[23]], \"entity_id\": [\"T5\"]}}"
}
]
}
] |
18644535_1 | Methylphenidate-associated enuresis in attention deficit hyperactivity disorder. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"associated\"]], \"start\": [[16]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"Methylphenidate\"]], \"start\": [[0]], \"entity_id\": [\"T3\"], \"Drug\": {\"text\": [[\"Methylphenidate\"]], \"start\": [[0]], \"entity_id\": [\"T6\"]}}, \"Effect\": {\"text\": [[\"enuresis\"]], \"start\": [[27]], \"entity_id\": [\"T5\"]}}"
}
]
}
] |
14740795_4 | To our knowledge, this is the first case report that demonstrates the occurrence of fever with low-dose amifostine therapy without the manifestation of accompanying rash or hypotension. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"occurrence\"]], \"start\": [[70]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"low-dose amifostine\"]], \"start\": [[95]], \"entity_id\": [\"T3\"], \"Dosage\": {\"text\": [[\"ow-dose\"]], \"start\": [[96]], \"entity_id\": [\"T8\"]}, \"Drug\": {\"text\": [[\"amifostine\"]], \"start\": [[104]], \"entity_id\": [\"T9\"]}}, \"Effect\": {\"text\": [[\"fever\"]], \"start\": [[84]], \"entity_id\": [\"T5\"]}, \"Subject\": {\"text\": [[\"the first case\"]], \"start\": [[26]], \"entity_id\": [\"T6\"]}, \"Speculated\": {\"text\": [[\"To our knowledge\"]], \"start\": [[0]], \"entity_id\": [\"T7\"], \"value\": true}}"
}
]
}
] |
3528096_1 | Administration of excessive insulin induced hypoglycemia within 4 to 8 hours, followed by rebound hyperglycemia. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[36]], \"entity_id\": [\"T6\"]}, \"Treatment\": {\"text\": [[\"Administration of excessive insulin\"]], \"start\": [[0]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"insulin\"]], \"start\": [[28]], \"entity_id\": [\"T8\"]}, \"Dosage\": {\"text\": [[\"excessive\"]], \"start\": [[18]], \"entity_id\": [\"T9\"]}, \"Duration\": {\"text\": [[\"4 to 8 hours\"]], \"start\": [[64]], \"entity_id\": [\"T10\"]}}, \"Effect\": {\"text\": [[\"hypoglycemia\", \"rebound hyperglycemia\"]], \"start\": [[44, 90]], \"entity_id\": [\"T7\"]}}"
}
]
}
] |
17122225_5 | In both cases, symptoms of autonomic instability and severe agitation started within hours of initiation of cyclobenzaprine and fully resolved within 3 days after discontinuing the proserotoninergic drugs. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"started\"]], \"start\": [[70]], \"entity_id\": [\"T8\"]}, \"Effect\": {\"text\": [[\"symptoms of autonomic instability and severe agitation\"]], \"start\": [[15]], \"entity_id\": [\"T6\"]}, \"Treatment\": {\"text\": [[\"within hours of initiation of cyclobenzaprine\"]], \"start\": [[78]], \"entity_id\": [\"T7\"], \"Drug\": {\"text\": [[\"cyclobenzaprine\"]], \"start\": [[108]], \"entity_id\": [\"T9\"]}, \"Time_elapsed\": {\"text\": [[\"within hours of initiation\"]], \"start\": [[78]], \"entity_id\": [\"T10\"]}}, \"Severity\": {\"text\": [[\"severe\"]], \"start\": [[53]], \"entity_id\": [\"T12\"], \"value\": \"High\"}}"
}
]
}
] |
10779995_2 | Secondary leukemia in a child with neuroblastoma while on oral etoposide: what is the cause? | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"in\"]], \"start\": [[19]], \"entity_id\": [\"T1\"]}, \"Subject\": {\"text\": [[\"a child with neuroblastoma\"]], \"start\": [[22]], \"entity_id\": [\"T2\"], \"Age\": {\"text\": [[\"child\"]], \"start\": [[24]], \"entity_id\": [\"T5\"]}}, \"Treatment\": {\"text\": [[\"oral etoposide\"]], \"start\": [[58]], \"entity_id\": [\"T3\"], \"Disorder\": {\"text\": [[\"neuroblastoma\"]], \"start\": [[35]], \"entity_id\": [\"T7\"]}, \"Route\": {\"text\": [[\"oral\"]], \"start\": [[58]], \"entity_id\": [\"T8\"]}, \"Drug\": {\"text\": [[\"etoposide\"]], \"start\": [[63]], \"entity_id\": [\"T9\"]}}, \"Effect\": {\"text\": [[\"Secondary leukemia\"]], \"start\": [[0]], \"entity_id\": [\"T4\"]}}"
}
]
}
] |
20666169_1 | Atorvastatin induced multiple organ failure. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[13]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"Atorvastatin\"]], \"start\": [[0]], \"entity_id\": [\"T4\"], \"Drug\": {\"text\": [[\"Atorvastatin\"]], \"start\": [[0]], \"entity_id\": [\"T7\"]}}, \"Effect\": {\"text\": [[\"multiple organ failure\"]], \"start\": [[21]], \"entity_id\": [\"T6\"]}}"
}
]
}
] |
19697589_3 | While serotonin syndrome has become more frequent in an overdose situation and when an interacting drug is given, the toxicity of SSIRs is less than that of most other psychiatric drugs. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"toxicity\"]], \"start\": [[118]], \"entity_id\": [\"T6\"]}, \"Effect\": {\"text\": [[\"serotonin syndrome\"]], \"start\": [[6]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"SSIRs\"]], \"start\": [[130]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"SSIRs\"]], \"start\": [[130]], \"entity_id\": [\"T7\"]}}}"
}
]
}
] |
7272895_1 | A 73-year-old woman with non-Hodgkin's lymphoma had two episodes of severe, bilateral, sensori-neural hearing loss after vincristine therapy. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"after\"]], \"start\": [[115]], \"entity_id\": [\"T5\"]}, \"Subject\": {\"text\": [[\"A 73-year-old woman with non-Hodgkin's lymphoma\"]], \"start\": [[0]], \"entity_id\": [\"T3\"], \"Age\": {\"text\": [[\"73-year-old\"]], \"start\": [[2]], \"entity_id\": [\"T7\"]}, \"Gender\": {\"text\": [[\"woman\"]], \"start\": [[14]], \"entity_id\": [\"T8\"]}}, \"Effect\": {\"text\": [[\"two episodes of severe, bilateral, sensori-neural hearing loss\"]], \"start\": [[52]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"vincristine therapy\"]], \"start\": [[121]], \"entity_id\": [\"T6\"], \"Drug\": {\"text\": [[\"vincristine\"]], \"start\": [[121]], \"entity_id\": [\"T11\"]}, \"Disorder\": {\"text\": [[\"non-Hodgkin's lymphoma\"]], \"start\": [[25]], \"entity_id\": [\"T12\"]}}, \"Severity\": {\"text\": [[\"severe\"]], \"start\": [[68]], \"entity_id\": [\"T10\"], \"value\": \"High\"}}"
}
]
}
] |
10885900_2 | Severe hemolytic uremic syndrome in an advanced ovarian cancer patient treated with carboplatin and gemcitabine. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"in\"]], \"start\": [[33]], \"entity_id\": [\"T5\"]}, \"Effect\": {\"text\": [[\"Severe hemolytic uremic syndrome\"]], \"start\": [[0]], \"entity_id\": [\"T4\"]}, \"Subject\": {\"text\": [[\"an advanced ovarian cancer patient\"]], \"start\": [[36]], \"entity_id\": [\"T6\"]}, \"Treatment\": {\"text\": [[\"carboplatin and gemcitabine\"]], \"start\": [[84]], \"entity_id\": [\"T7\"], \"Disorder\": {\"text\": [[\"ovarian cancer\"]], \"start\": [[48]], \"entity_id\": [\"T8\"]}, \"Drug\": {\"text\": [[\"carboplatin\"], [\"gemcitabine\"]], \"start\": [[84], [100]], \"entity_id\": [\"T10\", \"T11\"]}, \"Combination\": [{\"event_id\": \"E2\", \"event_type\": \"Combination\", \"Trigger\": {\"text\": [[\"and\"]], \"start\": [[96]], \"entity_id\": [\"T12\"]}, \"Drug\": {\"text\": [[\"carboplatin\"], [\"gemcitabine\"]], \"start\": [[84], [100]], \"entity_id\": [\"T10\", \"T11\"]}}]}}"
}
]
}
] |
2746565_2 | Ulcerative proctitis in juvenile systemic lupus erythematosus after ibuprofen treatment. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"after\"]], \"start\": [[62]], \"entity_id\": [\"T4\"]}, \"Effect\": {\"text\": [[\"Ulcerative proctitis in juvenile systemic lupus erythematosus\"]], \"start\": [[0]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"ibuprofen\"]], \"start\": [[68]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"ibuprofen\"]], \"start\": [[68]], \"entity_id\": [\"T6\"]}}}"
}
]
}
] |
9161656_1 | Acute asthma associated with sustained-release verapamil. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"associated\"]], \"start\": [[13]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"sustained-release verapamil\"]], \"start\": [[29]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"sustained-release verapamil\"]], \"start\": [[29]], \"entity_id\": [\"T7\"]}}, \"Effect\": {\"text\": [[\"Acute asthma\"]], \"start\": [[0]], \"entity_id\": [\"T6\"]}, \"Severity\": {\"text\": [[\"Acute\"]], \"start\": [[0]], \"entity_id\": [\"T8\"], \"value\": \"High\"}}"
}
]
}
] |
8749646_3 | The renal insufficiency of three patients and the timing of the seizures implicate accumulation of ofloxacin as a contributing factor. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"implicate\"]], \"start\": [[73]], \"entity_id\": [\"T8\"]}, \"Treatment\": {\"text\": [[\"accumulation of ofloxacin\"]], \"start\": [[83]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"ofloxacin\"]], \"start\": [[99]], \"entity_id\": [\"T10\"]}}, \"Effect\": {\"text\": [[\"renal insufficiency\", \"seizures\"]], \"start\": [[4, 64]], \"entity_id\": [\"T6\"]}, \"Subject\": {\"text\": [[\"three patients\"]], \"start\": [[27]], \"entity_id\": [\"T7\"], \"Population\": {\"text\": [[\"three\"]], \"start\": [[27]], \"entity_id\": [\"T9\"]}}}"
}
]
}
] |
2413037_1 | Hemolytic uremic syndrome in a patient on cis-platinum, vinblastine and bleomycin. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"in\"]], \"start\": [[26]], \"entity_id\": [\"T8\"]}, \"Treatment\": {\"text\": [[\"cis-platinum, vinblastine and bleomycin\"]], \"start\": [[42]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"cis-platinum\"], [\"vinblastine\"], [\"bleomycin\"]], \"start\": [[42], [56], [72]], \"entity_id\": [\"T9\", \"T10\", \"T11\"]}}, \"Subject\": {\"text\": [[\"a patient\"]], \"start\": [[29]], \"entity_id\": [\"T6\"]}, \"Effect\": {\"text\": [[\"Hemolytic uremic syndrome\"]], \"start\": [[0]], \"entity_id\": [\"T7\"]}}"
}
]
}
] |
15878975_1 | A previous review described data on 15 patients who experienced acute hemoglobinemia or hemoglobinuria following anti-D IGIV administration for ITP or secondary thrombocytopenia. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"following\"]], \"start\": [[103]], \"entity_id\": [\"T7\"]}, \"Subject\": {\"text\": [[\"15 patients\"]], \"start\": [[36]], \"entity_id\": [\"T5\"], \"Population\": {\"text\": [[\"15\"]], \"start\": [[36]], \"entity_id\": [\"T10\"]}}, \"Effect\": {\"text\": [[\"acute hemoglobinemia or hemoglobinuria\"]], \"start\": [[64]], \"entity_id\": [\"T6\"]}, \"Treatment\": {\"text\": [[\"anti-D IGIV\"]], \"start\": [[113]], \"entity_id\": [\"T8\"], \"Disorder\": {\"text\": [[\"ITP or secondary thrombocytopenia\"]], \"start\": [[144]], \"entity_id\": [\"T9\"]}, \"Drug\": {\"text\": [[\"anti-D IGIV\"]], \"start\": [[113]], \"entity_id\": [\"T11\"]}, \"Route\": {\"text\": [[\"administration\"]], \"start\": [[125]], \"entity_id\": [\"T12\"]}}}"
}
]
}
] |
2042691_1 | Amiodarone was discontinued, and thyrotoxicosis gradually abated. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Potential_therapeutic_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Potential_therapeutic_event\", \"Trigger\": {\"text\": [[\"was discontinued\"]], \"start\": [[11]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"Amiodarone\"]], \"start\": [[0]], \"entity_id\": [\"T4\"], \"Drug\": {\"text\": [[\"Amiodarone\"]], \"start\": [[0]], \"entity_id\": [\"T6\"]}}, \"Effect\": {\"text\": [[\"thyrotoxicosis gradually abated\"]], \"start\": [[33]], \"entity_id\": [\"T5\"]}}"
}
]
}
] |
11700998_1 | De novo absence status of late onset following withdrawal of lorazepam: a case report. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"following\"]], \"start\": [[37]], \"entity_id\": [\"T5\"]}, \"Effect\": {\"text\": [[\"De novo absence status of late onset\"]], \"start\": [[0]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"withdrawal of lorazepam\"]], \"start\": [[47]], \"entity_id\": [\"T4\"], \"Drug\": {\"text\": [[\"lorazepam\"]], \"start\": [[61]], \"entity_id\": [\"T6\"]}}}"
}
]
}
] |
19183077_1 | Tenofovir-associated nephrotoxicity in two HIV-infected adolescent males. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"associated\"]], \"start\": [[10]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"Tenofovir\"]], \"start\": [[0]], \"entity_id\": [\"T3\"], \"Drug\": {\"text\": [[\"Tenofovir\"]], \"start\": [[0]], \"entity_id\": [\"T11\"]}, \"Disorder\": {\"text\": [[\"HIV-infected\"]], \"start\": [[43]], \"entity_id\": [\"T12\"]}}, \"Effect\": {\"text\": [[\"nephrotoxicity\"]], \"start\": [[21]], \"entity_id\": [\"T5\"]}, \"Subject\": {\"text\": [[\"two HIV-infected adolescent males\"]], \"start\": [[39]], \"entity_id\": [\"T6\"], \"Population\": {\"text\": [[\"two\"]], \"start\": [[39]], \"entity_id\": [\"T8\"]}, \"Age\": {\"text\": [[\"adolescent\"]], \"start\": [[56]], \"entity_id\": [\"T9\"]}, \"Gender\": {\"text\": [[\"males\"]], \"start\": [[67]], \"entity_id\": [\"T10\"]}}}"
}
]
}
] |
17965530_1 | Reports of colonic perforation as a result of the administration of calcium polystyrene sulfonate and sorbitol are rare. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"result\"]], \"start\": [[36]], \"entity_id\": [\"T6\"]}, \"Effect\": {\"text\": [[\"colonic perforation\"]], \"start\": [[11]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"calcium polystyrene sulfonate\", \"sorbitol\"]], \"start\": [[68, 102]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"calcium polystyrene sulfonate\"], [\"sorbitol\"]], \"start\": [[68], [102]], \"entity_id\": [\"T8\", \"T9\"]}, \"Route\": {\"text\": [[\"the administration\"]], \"start\": [[46]], \"entity_id\": [\"T11\"]}, \"Combination\": [{\"event_id\": \"E2\", \"event_type\": \"Combination\", \"Trigger\": {\"text\": [[\"and\"]], \"start\": [[98]], \"entity_id\": [\"T10\"]}, \"Drug\": {\"text\": [[\"calcium polystyrene sulfonate\"], [\"sorbitol\"]], \"start\": [[68], [102]], \"entity_id\": [\"T8\", \"T9\"]}}]}}"
}
]
}
] |
8749646_1 | Improved awareness of and further investigation into the neurotoxic effects of ofloxacin may enhance its safe use. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"of\"]], \"start\": [[76]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"ofloxacin\"]], \"start\": [[79]], \"entity_id\": [\"T3\"], \"Drug\": {\"text\": [[\"ofloxacin\"]], \"start\": [[79]], \"entity_id\": [\"T6\"]}}, \"Effect\": {\"text\": [[\"neurotoxic effects\"]], \"start\": [[57]], \"entity_id\": [\"T4\"]}}"
}
]
}
] |
12013364_2 | Atypical neuroleptic malignant syndrome associated with olanzapine. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"associated\"]], \"start\": [[40]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"olanzapine\"]], \"start\": [[56]], \"entity_id\": [\"T4\"], \"Drug\": {\"text\": [[\"olanzapine\"]], \"start\": [[56]], \"entity_id\": [\"T6\"]}}, \"Effect\": {\"text\": [[\"Atypical neuroleptic malignant syndrome\"]], \"start\": [[0]], \"entity_id\": [\"T5\"]}}"
}
]
}
] |
20118434_4 | OBJECTIVE: The authors described a case of interferon-induced psychosis as a framework to review the literature and discuss the decision to pursue antiviral treatment in psychiatrically ill patients with hepatitis C. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[54]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"interferon\"]], \"start\": [[43]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"interferon\"]], \"start\": [[43]], \"entity_id\": [\"T9\"]}, \"Disorder\": {\"text\": [[\"hepatitis C\"]], \"start\": [[204]], \"entity_id\": [\"T10\"]}}, \"Effect\": {\"text\": [[\"psychosis\"]], \"start\": [[62]], \"entity_id\": [\"T6\"]}, \"Subject\": {\"text\": [[\"psychiatrically ill patients with hepatitis C\"]], \"start\": [[170]], \"entity_id\": [\"T3\"], \"Disorder\": {\"text\": [[\"psychiatrically ill\"]], \"start\": [[170]], \"entity_id\": [\"T7\"]}}}"
}
]
}
] |
1495728_4 | We believe that methotrexate represents a relatively effective alternative to surgery in patients with early unruptured tubal pregnancy, but suggest that it be used with caution in view of possible systemic toxicity. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"caution\"]], \"start\": [[170]], \"entity_id\": [\"T12\"]}, \"Subject\": {\"text\": [[\"patients with early unruptured tubal pregnancy\"]], \"start\": [[89]], \"entity_id\": [\"T9\"]}, \"Treatment\": {\"text\": [[\"methotrexate\"]], \"start\": [[16]], \"entity_id\": [\"T10\"], \"Drug\": {\"text\": [[\"methotrexate\"]], \"start\": [[16]], \"entity_id\": [\"T15\"]}, \"Disorder\": {\"text\": [[\"early unruptured tubal pregnancy\"]], \"start\": [[103]], \"entity_id\": [\"T16\"]}}, \"Effect\": {\"text\": [[\"systemic toxicity\"]], \"start\": [[198]], \"entity_id\": [\"T13\"]}, \"Speculated\": {\"text\": [[\"suggest\", \"possible\"]], \"start\": [[141, 189]], \"entity_id\": [\"T11\"], \"value\": true}}"
}
]
}
] |
16371793_12 | After intravitreal injection of triamcinolone acetonide, cataract may rapidly develop in eyes that have been intensively treated, topically and systemically, by corticosteroids for several years. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"develop\"]], \"start\": [[78]], \"entity_id\": [\"T9\"]}, \"Treatment\": {\"text\": [[\"intravitreal injection of triamcinolone acetonide\"]], \"start\": [[6]], \"entity_id\": [\"T6\"], \"Route\": {\"text\": [[\"intravitreal injection\"]], \"start\": [[6]], \"entity_id\": [\"T10\"]}, \"Drug\": {\"text\": [[\"triamcinolone acetonide\"]], \"start\": [[32]], \"entity_id\": [\"T11\"]}}, \"Effect\": {\"text\": [[\"cataract\"]], \"start\": [[57]], \"entity_id\": [\"T7\"]}, \"Speculated\": {\"text\": [[\"may\"]], \"start\": [[66]], \"entity_id\": [\"T8\"], \"value\": true}}"
}
]
}
] |
17277758_1 | Acute endophthalmitis following intravitreal bevacizumab (Avastin) injection. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"following\"]], \"start\": [[22]], \"entity_id\": [\"T5\"]}, \"Effect\": {\"text\": [[\"Acute endophthalmitis\"]], \"start\": [[0]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"intravitreal bevacizumab (Avastin) injection\"]], \"start\": [[32]], \"entity_id\": [\"T6\"], \"Route\": {\"text\": [[\"intravitreal\"], [\"injection\"]], \"start\": [[32], [67]], \"entity_id\": [\"T7\", \"T9\"]}, \"Drug\": {\"text\": [[\"bevacizumab\"]], \"start\": [[45]], \"entity_id\": [\"T8\"]}}}"
}
]
}
] |
25957434_3 | We report a case of bullous eruption, one month after starting nicardipine and lercanidipine. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"after\"]], \"start\": [[48]], \"entity_id\": [\"T6\"]}, \"Treatment\": {\"text\": [[\"starting nicardipine and lercanidipine.\"]], \"start\": [[54]], \"entity_id\": [\"T7\"], \"Time_elapsed\": {\"text\": [[\"one month\"]], \"start\": [[38]], \"entity_id\": [\"T9\"]}, \"Drug\": {\"text\": [[\"nicardipine\"], [\"lercanidipine\"]], \"start\": [[63], [79]], \"entity_id\": [\"T10\", \"T11\"]}, \"Combination\": [{\"event_id\": \"E2\", \"event_type\": \"Combination\", \"Trigger\": {\"text\": [[\"and\"]], \"start\": [[75]], \"entity_id\": [\"T12\"]}, \"Drug\": {\"text\": [[\"nicardipine\"], [\"lercanidipine\"]], \"start\": [[63], [79]], \"entity_id\": [\"T10\", \"T11\"]}}]}, \"Effect\": {\"text\": [[\"bullous eruption,\"]], \"start\": [[20]], \"entity_id\": [\"T8\"]}}"
}
]
}
] |
1775411_2 | Pulmonary fibrosis associated with nabumetone. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"associated\"]], \"start\": [[19]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"nabumetone\"]], \"start\": [[35]], \"entity_id\": [\"T3\"], \"Drug\": {\"text\": [[\"nabumetone\"]], \"start\": [[35]], \"entity_id\": [\"T6\"]}}, \"Effect\": {\"text\": [[\"Pulmonary fibrosis\"]], \"start\": [[0]], \"entity_id\": [\"T5\"]}}"
}
]
}
] |
19660974_2 | The ability of tumor necrosis factor (TNF)-alpha inhibitors to impair pivotal pro-inflammatory host defenses may facilitate the development of disseminated cryptococcosis. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"development\"]], \"start\": [[128]], \"entity_id\": [\"T5\"]}, \"Effect\": {\"text\": [[\"disseminated cryptococcosis\"]], \"start\": [[143]], \"entity_id\": [\"T6\"]}, \"Treatment\": {\"text\": [[\"tumor necrosis factor (TNF)-alpha inhibitors\"]], \"start\": [[15]], \"entity_id\": [\"T8\"], \"Drug\": {\"text\": [[\"tumor necrosis factor (TNF)-alpha inhibitors\"]], \"start\": [[15]], \"entity_id\": [\"T9\"]}}, \"Speculated\": {\"text\": [[\"may facilitate\"]], \"start\": [[109]], \"entity_id\": [\"T7\"], \"value\": true}}"
}
]
}
] |
6529939_4 | This was accepted as evidence for propranolol being the cause of this conduction disorder. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"cause\"]], \"start\": [[56]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"propranolol\"]], \"start\": [[34]], \"entity_id\": [\"T4\"], \"Drug\": {\"text\": [[\"propranolol\"]], \"start\": [[34]], \"entity_id\": [\"T6\"]}}, \"Effect\": {\"text\": [[\"conduction disorder\"]], \"start\": [[70]], \"entity_id\": [\"T5\"]}}"
}
]
}
] |
1517501_4 | We report a third case of a 6-week-old infant with Escherichia coli sepsis who received ampicillin and other antibiotics and subsequently developed TEN. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"developed\"]], \"start\": [[138]], \"entity_id\": [\"T12\"]}, \"Subject\": {\"text\": [[\"6-week-old infant with Escherichia coli sepsis\"]], \"start\": [[28]], \"entity_id\": [\"T8\"], \"Age\": {\"text\": [[\"6-week-old\"], [\"infant\"]], \"start\": [[28], [39]], \"entity_id\": [\"T13\", \"T14\"]}}, \"Treatment\": {\"text\": [[\"received ampicillin and other antibiotics\"]], \"start\": [[79]], \"entity_id\": [\"T10\"], \"Drug\": {\"text\": [[\"ampicillin\"], [\"other antibiotics\"]], \"start\": [[88], [103]], \"entity_id\": [\"T15\", \"T16\"]}, \"Disorder\": {\"text\": [[\"Escherichia coli sepsis\"]], \"start\": [[51]], \"entity_id\": [\"T18\"]}, \"Combination\": [{\"event_id\": \"E2\", \"event_type\": \"Combination\", \"Trigger\": {\"text\": [[\"and\"]], \"start\": [[99]], \"entity_id\": [\"T17\"]}, \"Drug\": {\"text\": [[\"ampicillin\"], [\"other antibiotics\"]], \"start\": [[88], [103]], \"entity_id\": [\"T15\", \"T16\"]}}]}, \"Effect\": {\"text\": [[\"TEN\"]], \"start\": [[148]], \"entity_id\": [\"T11\"]}}"
}
]
}
] |
18379937_2 | PURPOSE: To report a case of bilateral anterior uveitis associated with ovulation induction therapy using clomiphene citrate. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"associated\"]], \"start\": [[56]], \"entity_id\": [\"T5\"]}, \"Subject\": {\"text\": [[\"case\"]], \"start\": [[21]], \"entity_id\": [\"T3\"]}, \"Effect\": {\"text\": [[\"bilateral anterior uveitis\"]], \"start\": [[29]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"ovulation induction therapy using clomiphene citrate\"]], \"start\": [[72]], \"entity_id\": [\"T6\"], \"Drug\": {\"text\": [[\"clomiphene citrate\"]], \"start\": [[106]], \"entity_id\": [\"T7\"]}}}"
}
]
}
] |
2979256_1 | A 57-year-old woman presented with a 3-week history of dysphagia for solids, 6 months after starting treatment with nifedipine. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"presented\"]], \"start\": [[20]], \"entity_id\": [\"T5\"]}, \"Subject\": {\"text\": [[\"A 57-year-old woman\"]], \"start\": [[0]], \"entity_id\": [\"T3\"], \"Age\": {\"text\": [[\"57-year-old\"]], \"start\": [[2]], \"entity_id\": [\"T7\"]}, \"Gender\": {\"text\": [[\"woman\"]], \"start\": [[14]], \"entity_id\": [\"T8\"]}}, \"Effect\": {\"text\": [[\"dysphagia for solids\"]], \"start\": [[55]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"nifedipine\"]], \"start\": [[116]], \"entity_id\": [\"T6\"], \"Time_elapsed\": {\"text\": [[\"6 months\"]], \"start\": [[77]], \"entity_id\": [\"T10\"]}, \"Drug\": {\"text\": [[\"nifedipine\"]], \"start\": [[116]], \"entity_id\": [\"T11\"]}}}"
}
]
}
] |
15097937_1 | Although combinations of belladonna, ergotamine, and phenobarbital have been used for medical treatment of menopausal symptoms since the 1960s, this is the first known case report of its association with anticonvulsant hypersensitivity syndrome. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"association\"]], \"start\": [[187]], \"entity_id\": [\"T6\"]}, \"Treatment\": {\"text\": [[\"combinations of belladonna, ergotamine, and phenobarbital\"]], \"start\": [[9]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"belladonna\"], [\"ergotamine\"], [\"phenobarbital\"]], \"start\": [[25], [37], [53]], \"entity_id\": [\"T9\", \"T10\", \"T11\"]}, \"Disorder\": {\"text\": [[\"menopausal symptom\"]], \"start\": [[107]], \"entity_id\": [\"T13\"]}, \"Combination\": [{\"event_id\": \"E2\", \"event_type\": \"Combination\", \"Trigger\": {\"text\": [[\"and\"]], \"start\": [[49]], \"entity_id\": [\"T12\"]}, \"Drug\": {\"text\": [[\"belladonna\"], [\"ergotamine\"], [\"phenobarbital\"]], \"start\": [[25], [37], [53]], \"entity_id\": [\"T9\", \"T10\", \"T11\"]}}]}, \"Effect\": {\"text\": [[\"anticonvulsant hypersensitivity syndrome\"]], \"start\": [[204]], \"entity_id\": [\"T7\"]}}"
}
]
}
] |
2728526_2 | Rifampin can be associated with severe adverse effects such as hepatitis, acute renal failure, hemolytic anemia, and thrombocytopenia. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"associated\"]], \"start\": [[16]], \"entity_id\": [\"T10\"]}, \"Treatment\": {\"text\": [[\"Rifampin\"]], \"start\": [[0]], \"entity_id\": [\"T9\"], \"Drug\": {\"text\": [[\"Rifampin\"]], \"start\": [[0]], \"entity_id\": [\"T12\"]}}, \"Effect\": {\"text\": [[\"hepatitis, acute renal failure, hemolytic anemia, and thrombocytopenia\"]], \"start\": [[63]], \"entity_id\": [\"T11\"]}, \"Severity\": {\"text\": [[\"severe\"]], \"start\": [[32]], \"entity_id\": [\"T13\"], \"value\": \"High\"}}"
}
]
}
] |
2051906_2 | It is believed that this is the first reported case of reversible azathioprine-induced cholestasis associated with histological evidence of bile duct injury. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[79]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"azathioprine\"]], \"start\": [[66]], \"entity_id\": [\"T3\"], \"Drug\": {\"text\": [[\"azathioprine\"]], \"start\": [[66]], \"entity_id\": [\"T6\"]}}, \"Effect\": {\"text\": [[\"cholestasis\"]], \"start\": [[87]], \"entity_id\": [\"T4\"]}}"
}
]
}
] |
9554064_4 | We present a fatal case of subacute methanol toxicity with associated diffuse brain involvement, including bilateral putaminal necrosis and cerebral edema with ventricular compression. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"associated\"]], \"start\": [[59]], \"entity_id\": [\"T14\"]}, \"Treatment\": {\"text\": [[\"methanol\"]], \"start\": [[36]], \"entity_id\": [\"T13\"], \"Drug\": {\"text\": [[\"methanol\"]], \"start\": [[36]], \"entity_id\": [\"T16\"]}}, \"Effect\": {\"text\": [[\"diffuse brain involvement, including bilateral putaminal necrosis and cerebral edema with ventricular compression\"]], \"start\": [[70]], \"entity_id\": [\"T15\"]}, \"Severity\": {\"text\": [[\"fatal\"]], \"start\": [[13]], \"entity_id\": [\"T17\"], \"value\": \"High\"}}"
}
]
}
] |
9653495_6 | Patients with inoperable or metastatic colorectal cancer were randomized to receive monthly FU 400 mg/m2/day plus LV 20 mg/m2/day as intravenous push daily for five days, or FU alone. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Potential_therapeutic_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Potential_therapeutic_event\", \"Trigger\": {\"text\": [[\"receive\"]], \"start\": [[76]], \"entity_id\": [\"T14\"]}, \"Subject\": {\"text\": [[\"Patients with inoperable or metastatic colorectal cancer\"]], \"start\": [[0]], \"entity_id\": [\"T10\"]}, \"Treatment\": {\"text\": [[\"monthly FU 400 mg/m2/day plus LV 20 mg/m2/day as intravenous push daily for five days\"]], \"start\": [[84]], \"entity_id\": [\"T13\"], \"Disorder\": {\"text\": [[\"metastatic colorectal cancer\"], [\"inoperable\"]], \"start\": [[28], [14]], \"entity_id\": [\"T12\", \"T24\"]}, \"Dosage\": {\"text\": [[\"400 mg/m2/day\"], [\"20 mg/m2/day\"]], \"start\": [[95], [117]], \"entity_id\": [\"T17\", \"T21\"]}, \"Drug\": {\"text\": [[\"FU\"], [\"LV\"]], \"start\": [[92], [114]], \"entity_id\": [\"T16\", \"T20\"]}, \"Route\": {\"text\": [[\"intravenous push\"]], \"start\": [[133]], \"entity_id\": [\"T23\"]}, \"Freq\": {\"text\": [[\"daily\"], [\"monthly\"]], \"start\": [[150], [84]], \"entity_id\": [\"T18\", \"T22\"]}, \"Duration\": {\"text\": [[\"five days\"]], \"start\": [[160]], \"entity_id\": [\"T25\"]}, \"Combination\": [{\"event_id\": \"E2\", \"event_type\": \"Combination\", \"Trigger\": {\"text\": [[\"plus\"]], \"start\": [[109]], \"entity_id\": [\"T19\"]}, \"Drug\": {\"text\": [[\"FU\"], [\"LV\"]], \"start\": [[92], [114]], \"entity_id\": [\"T16\", \"T20\"]}}]}}"
}
]
}
] |
9347384_3 | The present report suggests that clarithromycin coadministration induces increased plasma carbamazepine concentrations, which may result in carbamazepine toxicity. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induces\"]], \"start\": [[65]], \"entity_id\": [\"T10\"]}, \"Treatment\": {\"text\": [[\"clarithromycin\", \"carbamazepine\", \"carbamazepine\"]], \"start\": [[33, 90, 140]], \"entity_id\": [\"T9\"], \"Drug\": {\"text\": [[\"clarithromycin\"]], \"start\": [[33]], \"entity_id\": [\"T14\"]}}, \"Effect\": {\"text\": [[\"increased plasma carbamazepine concentrations\", \"carbamazepine toxicity.\"]], \"start\": [[73, 140]], \"entity_id\": [\"T12\"]}, \"Subject\": {\"text\": [[\"carbamazepine\"]], \"start\": [[90]], \"entity_id\": [\"T15\"]}, \"Speculated\": {\"text\": [[\"may\"]], \"start\": [[126]], \"entity_id\": [\"T11\"], \"value\": true}}"
}
]
}
] |
11850606_2 | In this case, interferon alpha induced polymyositis and cardiomyopathy is diagnosed in a 33-yr-old male patient with history of chronic hepatitis B. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[31]], \"entity_id\": [\"T7\"]}, \"Subject\": {\"text\": [[\"a 33-yr-old male patient with history of chronic hepatitis B\"]], \"start\": [[87]], \"entity_id\": [\"T5\"], \"Age\": {\"text\": [[\"33-yr-old\"]], \"start\": [[89]], \"entity_id\": [\"T9\"]}, \"Gender\": {\"text\": [[\"male\"]], \"start\": [[99]], \"entity_id\": [\"T10\"]}}, \"Treatment\": {\"text\": [[\"interferon alpha\"]], \"start\": [[14]], \"entity_id\": [\"T6\"], \"Drug\": {\"text\": [[\"interferon alpha\"]], \"start\": [[14]], \"entity_id\": [\"T12\"]}, \"Disorder\": {\"text\": [[\"history of chronic hepatitis B\"]], \"start\": [[117]], \"entity_id\": [\"T13\"]}}, \"Effect\": {\"text\": [[\"polymyositis and cardiomyopathy\"]], \"start\": [[39]], \"entity_id\": [\"T8\"]}}"
}
]
}
] |
16005413_2 | To describe the potential for interaction between opioids and serotonergic antidepressants leading to the development of serotonin syndrome (SS), mechanism of the interaction, and the spectrum of SS in elderly residents of a long-term care facility. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"leading\"]], \"start\": [[91]], \"entity_id\": [\"T11\"]}, \"Treatment\": {\"text\": [[\"opioids\", \"serotonergic antidepressants\"]], \"start\": [[50, 62]], \"entity_id\": [\"T10\"], \"Drug\": {\"text\": [[\"opioids\"], [\"serotonergic antidepressants\"]], \"start\": [[50], [62]], \"entity_id\": [\"T16\", \"T17\"]}, \"Combination\": [{\"event_id\": \"E2\", \"event_type\": \"Combination\", \"Trigger\": {\"text\": [[\"interaction\"]], \"start\": [[30]], \"entity_id\": [\"T15\"]}, \"Drug\": {\"text\": [[\"opioids\"], [\"serotonergic antidepressants\"]], \"start\": [[50], [62]], \"entity_id\": [\"T16\", \"T17\"]}}]}, \"Effect\": {\"text\": [[\"serotonin syndrome\"]], \"start\": [[121]], \"entity_id\": [\"T12\"]}, \"Subject\": {\"text\": [[\"elderly residents\"]], \"start\": [[202]], \"entity_id\": [\"T13\"], \"Age\": {\"text\": [[\"elderly\"]], \"start\": [[202]], \"entity_id\": [\"T14\"]}}}"
}
]
}
] |
480917_2 | Erythema multiforme bullosum due to rifampicin. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"due\"]], \"start\": [[29]], \"entity_id\": [\"T4\"]}, \"Effect\": {\"text\": [[\"Erythema multiforme bullosum\"]], \"start\": [[0]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"rifampicin\"]], \"start\": [[36]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"rifampicin\"]], \"start\": [[36]], \"entity_id\": [\"T6\"]}}}"
}
]
}
] |
2554727_4 | We describe a patient with acute leukemia who developed Horner's syndrome and a severe demyelinating peripheral neuropathy leading to death after receiving high-dose cytosine arabinoside. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"developed\"]], \"start\": [[46]], \"entity_id\": [\"T7\"]}, \"Treatment\": {\"text\": [[\"high-dose cytosine arabinoside.\"]], \"start\": [[156]], \"entity_id\": [\"T8\"], \"Disorder\": {\"text\": [[\"acute leukemia\"]], \"start\": [[27]], \"entity_id\": [\"T12\"]}, \"Drug\": {\"text\": [[\"cytosine arabinoside\"]], \"start\": [[166]], \"entity_id\": [\"T14\"]}, \"Dosage\": {\"text\": [[\"high-dose\"]], \"start\": [[156]], \"entity_id\": [\"T15\"]}}, \"Effect\": {\"text\": [[\"Horner's syndrome and a severe demyelinating peripheral neuropathy leading to death\"]], \"start\": [[56]], \"entity_id\": [\"T9\"]}, \"Subject\": {\"text\": [[\"a patient with acute leukemia\"]], \"start\": [[12]], \"entity_id\": [\"T10\"]}, \"Severity\": {\"text\": [[\"acute\"]], \"start\": [[27]], \"entity_id\": [\"T13\"], \"value\": \"High\"}}"
}
]
}
] |
1509179_3 | This profile should trigger a "red flag" as to the possibility of phenobarbital behavioral side effects or exacerbation of preexisting maladaptive behaviors. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"trigger\"]], \"start\": [[20]], \"entity_id\": [\"T7\"]}, \"Treatment\": {\"text\": [[\"phenobarbital\"]], \"start\": [[66]], \"entity_id\": [\"T6\"], \"Drug\": {\"text\": [[\"phenobarbital\"]], \"start\": [[66]], \"entity_id\": [\"T9\"]}}, \"Effect\": {\"text\": [[\"behavioral side effects or exacerbation of preexisting maladaptive behaviors\"]], \"start\": [[80]], \"entity_id\": [\"T8\"]}, \"Speculated\": {\"text\": [[\"possibility\"]], \"start\": [[51]], \"entity_id\": [\"T5\"], \"value\": true}}"
}
]
}
] |
15580406_2 | Retinal abnormalities, including retinal hemorrhage and "cotton-wool" spots, often occur within the first 8 weeks in the course of interferon therapy in patients with chronic hepatitis C. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"occur\"]], \"start\": [[83]], \"entity_id\": [\"T8\"]}, \"Effect\": {\"text\": [[\"Retinal abnormalities, including retinal hemorrhage and \\\"cotton-wool\\\" spots\"]], \"start\": [[0]], \"entity_id\": [\"T7\"]}, \"Treatment\": {\"text\": [[\"interferon\"]], \"start\": [[131]], \"entity_id\": [\"T9\"], \"Time_elapsed\": {\"text\": [[\"8 weeks\"]], \"start\": [[106]], \"entity_id\": [\"T12\"]}, \"Drug\": {\"text\": [[\"interferon\"]], \"start\": [[131]], \"entity_id\": [\"T13\"]}, \"Disorder\": {\"text\": [[\"chronic hepatitis C\"]], \"start\": [[167]], \"entity_id\": [\"T14\"]}}, \"Subject\": {\"text\": [[\"patients with chronic hepatitis C\"]], \"start\": [[153]], \"entity_id\": [\"T10\"]}}"
}
]
}
] |
12581772_2 | Rapamycin/sirolimus-induced pneumonitis has been described previously in renal transplant recipients, and this report describes a stable heart-lung transplant recipient who developed a pulmonary infiltrate that reversed after ceasing SR therapy. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[20]], \"entity_id\": [\"T9\"]}, \"Treatment\": {\"text\": [[\"Rapamycin/sirolimus\"]], \"start\": [[0]], \"entity_id\": [\"T8\"], \"Drug\": {\"text\": [[\"Rapamycin\"], [\"sirolimus\"]], \"start\": [[0], [10]], \"entity_id\": [\"T11\", \"T12\"]}, \"Combination\": [{\"event_id\": \"E2\", \"event_type\": \"Combination\", \"Trigger\": {\"text\": [[\"/\"]], \"start\": [[9]], \"entity_id\": [\"T13\"]}, \"Drug\": {\"text\": [[\"Rapamycin\"], [\"sirolimus\"]], \"start\": [[0], [10]], \"entity_id\": [\"T11\", \"T12\"]}}]}, \"Effect\": {\"text\": [[\"pneumonitis\"]], \"start\": [[28]], \"entity_id\": [\"T10\"]}}"
}
]
}
] |